Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pyloriinfection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

Citation
M. Dojo et al., Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pyloriinfection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan, DIG LIVER D, 33(8), 2001, pp. 671-675
Citations number
33
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Gastroenerology and Hepatology
Journal title
DIGESTIVE AND LIVER DISEASE
ISSN journal
1590-8658 → ACNP
Volume
33
Issue
8
Year of publication
2001
Pages
671 - 675
Database
ISI
SICI code
1590-8658(200111)33:8<671:EOCGPO>2.0.ZU;2-K
Abstract
Background, Omeprazole is mainly metabolized by cytochrome P450 2C19 (CYP2C 19) in the liver. Rabeprazole, on the other hand, is mainly metabolized to thioether-rabeprazole via a non-enzymatic pathway and partially metabolized to demethylated-rabeprazole by CYP2C19 in liver. CYP2C19 status may affect cure rate for Helicobacter pylori infection with proton pump inhibitor tri ple therapy. Aim. To investigate whether genetic polymorphism of CYP2C19 and selected pr oton pump inhibitors (omeprazole or rabeprazole) were associated with cure rate for Helicobacter pylori infection using triple therapy with omeprazole or rabeprazole, amoxicillin, and clarithromycin. Methods. A total of 170 Helicobacter pylori-positive patients with chronic gastritis were randomized to receive one of the following Helicobacter pylo ri eradication regimens; DAC (omeprazole 20 mg bd, amoxycillin 750 mg bd an d clarithromycin 400 mg bd for I week) and PAC (rabeprazole 20 mg bd, amoxy cillin 750 mg bd and clarithromycin 400 mg bd for I week). The CYP2C19 geno type; wild-type or two mutant genes (m1 in exon 5 and m2 in exon 4), or bot h, were identified by polymerase chain reaction-restriction fragment length polymorphism. Results. In OAC regimen, cure I-ate (per protocol analysis) was 73.3% in ho mozygous extensive metabolizers, 86.1% in heterozygous extensive metabolize rs, and 85.0% in poor metabolizers. In PAC regimen, the cure rate was 81.0% in homozygous extensive metabolizers, 82.9% in heterozygous extensive meta bolizers, and 87.5% in poor metabolizers. Cure rate was not significantly d ifferent between the CYP2C19 genotypes in both regimens. Conclusion. Triple therapy with proton pump inhibitor (omeprazole or rabepr azole), amoxycillin, and clarithromycin is sufficiently effective in cure o f Helicobacter pylori infection regardless of CYP2C19 status.